結合組織疾患を伴う間質性肺疾患の成人患者におけるベリムマブの有効性と安全性に関する研究

基本情報

NCT ID

NCT06572384

ステータス

募集中

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

440

治験依頼者名

GlaxoSmithKline

概要

Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the leading cause of death in participants with these conditions. The study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabilization and/or improvement of lung function and improve symptoms associated with ILD with an acceptable safety profile.

対象疾患

介入

依頼者（Sponsor）